About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
SOHO Highlights: State of the Art and Next Questions
2023
2022
2021
Event
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Surveying the Induction and Maintenance Therapy Landscape in Newly Diagnosed, and Approaches to Early R/R MM
By
SOHO Highlights: State of the Art and Next Questions
FEATURING
Sagar Lonial
By
SOHO Highlights: State of the Art and Next Questions
FEATURING
Sagar Lonial
234 views
February 9, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
2021
14:40
SOHO Highlights: State of the Art and Next Questions
Newly Diagnosed ALCL/PTCL State of the Art: How Can We Improve Outco…
Feat.
K. Savage
13:36
SOHO Highlights: State of the Art and Next Questions
SOHO Updates on 1L FL: Does RT+/-(R)CVP Improve PFS in Limited Stage…
Feat.
R. Marcus
14:42
SOHO Highlights: State of the Art and Next Questions
SOHO Highlights on Non-Bulky cHL: Can We Treat Early Disease With Sh…
Feat.
D. Straus
09:24
SOHO Highlights: State of the Art and Next Questions
ECHELON-1 Data on Brentuximab Vedotin for Frontline Advanced cHL: Ex…
Feat.
D. Straus
10:47
SOHO Highlights: State of the Art and Next Questions
Surveying the Induction and Maintenance Therapy Landscape in Newly D…
Feat.
S. Lonial
20:52
SOHO Highlights: State of the Art and Next Questions
MM State of the Art: Approaches to Smoldering, MRD as a Prognostic M…
Feat.
S. Lonial
29:37
SOHO Highlights: State of the Art and Next Questions
CML State of the Art: Dasatinib/Imatinib Dose Optimization, STAMPi A…
Feat.
M. Deininger
34:50
SOHO Highlights: State of the Art and Next Questions
MPNs State of the Art: What Is the Response to Ruxolitinib vs. BAT? …
Feat.
S. Verstovsek
27:43
SOHO Highlights: State of the Art and Next Questions
MDS State of the Art: Imetelstat/Roxadustat for Anemia, Oral HMAs, A…
Feat.
G. Garcia-Manero
11:39
SOHO Highlights: State of the Art and Next Questions
Early Stage cHL Management: Bulky vs. Non-bulky Disease, Better Chem…
Feat.
D. Straus
14:25
SOHO Highlights: State of the Art and Next Questions
SOHO Highlights on Untreated MCL: How Does Deferred Therapy Work? Wh…
Feat.
J. Cohen
19:43
SOHO Highlights: State of the Art and Next Questions
SOHO Highlights on R/R MCL: The Role of BTKis, CAR-T, and Chemothera…
Feat.
J. Cohen
20:07
SOHO Highlights: State of the Art and Next Questions
R/R PTCL State of the Art: Allo-SCT vs. Auto-SCT? Can Pralatrexate C…
Feat.
K. Savage
18:07
SOHO Highlights: State of the Art and Next Questions
SOHO Updates on 1L MZL: Can RT Help in Early Stage MALToma? Is R-Ben…
Feat.
R. Marcus
34:46
SOHO Highlights: State of the Art and Next Questions
DLBCL State of the Art: Does Gene Expression Help With the Disease? …
Feat.
S. Dave
24:38
SOHO Highlights: State of the Art and Next Questions
Dana-Farber CLL State of the Art: A Review of BTK Inhibitors Data in…
Feat.
J. Brown
24:52
SOHO Highlights: State of the Art and Next Questions
CAR-T State of the Art: What Therapies Will Be Available in the Next…
Feat.
S. Giralt
29:51
SOHO Highlights: State of the Art and Next Questions
AML State of the Art: Older Patients Management, MRD, Total Oral Com…
Feat.
A. Zeidan
29:28
SOHO Highlights: State of the Art and Next Questions
ALL State of the Art at MD Anderson: Hyper-CVAD Combinations, MiniHC…
Feat.
H. Kantarjian